Psoriatic Arthritis - Pipeline Review, H2 2017

Date: November 21, 2017
Pages: 244
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P8BDC2BEC63EN
Leaflet:

Download PDF Leaflet

Psoriatic Arthritis - Pipeline Review, H2 2017
Psoriatic Arthritis - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis - Pipeline Review, H2 2017, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape.

Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain and lower back pain. Risk factors include age, family history and psoriasis. Treatment includes NSAIDs, immunosuppressants and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriatic Arthritis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 5, 8, 10, 1, 24, 9 and 3 respectively.

Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Psoriatic Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Psoriatic Arthritis - Overview
Psoriatic Arthritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Psoriatic Arthritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Psoriatic Arthritis - Companies Involved in Therapeutics Development
3SBio Inc
AbbVie Inc
AbGenomics International Inc
Aclaris Therapeutics Inc
Adello Biologics LLC
Allergan Plc
Alteogen Inc
Amgen Inc
Biocon Ltd
Bionovis SA
Coherus BioSciences Inc
Eli Lilly and Co
Formycon AG
Forward Pharma AS
Fresenius SE & Co KGaA
Galapagos NV
Genor BioPharma Co Ltd
Immunwork Inc
Innovent Biologics Inc
Johnson & Johnson
KPI Therapeutics Inc
Morphotek Inc
Mycenax Biotech Inc
Nichi-Iko Pharmaceutical Co Ltd
Novo Nordisk AS
Nuevolution AB
Oncobiologics Inc
Pfizer Inc
Reliance Life Sciences Pvt Ltd
Rigel Pharmaceuticals Inc
Sandoz International GmbH
Sun Pharma Advanced Research Company Ltd
SynAct Pharma AB
UCB SA
Xbrane Biopharma AB
Psoriatic Arthritis - Drug Profiles
AbGn-168H - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
AGR-131 - Drug Profile
AK-101 - Drug Profile
AK-111 - Drug Profile
AP-1189 - Drug Profile
apremilast - Drug Profile
ATI-450 - Drug Profile
baricitinib - Drug Profile
bimekizumab - Drug Profile
certolizumab pegol - Drug Profile
certolizumab pegol biosimilar - Drug Profile
clazakizumab - Drug Profile
dalazatide - Drug Profile
dimethyl fumarate - Drug Profile
DNX-114 - Drug Profile
DNX-514 - Drug Profile
etanercept - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
filgotinib - Drug Profile
golimumab biosimilar - Drug Profile
golimumab biosimilar - Drug Profile
GSK-3050002 - Drug Profile
guselkumab - Drug Profile
HEISCO-III-002 - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
INV-17 - Drug Profile
ixekizumab - Drug Profile
liraglutide - Drug Profile
risankizumab - Drug Profile
Small Molecule to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile
Small Molecule to Inhibit IRAK1/4 for Arthritis and Psoriasis - Drug Profile
Small Molecules to Antagonize RORgamma for Rheumatoid Arthritis, Inflammatory Bowel Disease, Dermatology and Psoriatic Arthritis - Drug Profile
TE-2122 - Drug Profile
TE-2158 - Drug Profile
tildrakizumab - Drug Profile
tofacitinib citrate - Drug Profile
upadacitinib tartrate - Drug Profile
ustekinumab biosimilar - Drug Profile
ustekinumab biosimilar - Drug Profile
ustekinumab biosimilar - Drug Profile
VTP-43742 - Drug Profile
Psoriatic Arthritis - Dormant Projects
Psoriatic Arthritis - Discontinued Products
Psoriatic Arthritis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Psoriatic Arthritis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Psoriatic Arthritis - Pipeline by 3SBio Inc, H2 2017
Psoriatic Arthritis - Pipeline by AbbVie Inc, H2 2017
Psoriatic Arthritis - Pipeline by AbGenomics International Inc, H2 2017
Psoriatic Arthritis - Pipeline by Aclaris Therapeutics Inc, H2 2017
Psoriatic Arthritis - Pipeline by Adello Biologics LLC, H2 2017
Psoriatic Arthritis - Pipeline by Allergan Plc, H2 2017
Psoriatic Arthritis - Pipeline by Alteogen Inc, H2 2017
Psoriatic Arthritis - Pipeline by Amgen Inc, H2 2017
Psoriatic Arthritis - Pipeline by Biocon Ltd, H2 2017
Psoriatic Arthritis - Pipeline by Bionovis SA, H2 2017
Psoriatic Arthritis - Pipeline by Coherus BioSciences Inc, H2 2017
Psoriatic Arthritis - Pipeline by Eli Lilly and Co, H2 2017
Psoriatic Arthritis - Pipeline by Formycon AG, H2 2017
Psoriatic Arthritis - Pipeline by Forward Pharma AS, H2 2017
Psoriatic Arthritis - Pipeline by Fresenius SE & Co KGaA, H2 2017
Psoriatic Arthritis - Pipeline by Galapagos NV, H2 2017
Psoriatic Arthritis - Pipeline by Genor BioPharma Co Ltd, H2 2017
Psoriatic Arthritis - Pipeline by Immunwork Inc, H2 2017
Psoriatic Arthritis - Pipeline by Innovent Biologics Inc, H2 2017
Psoriatic Arthritis - Pipeline by Johnson & Johnson, H2 2017
Psoriatic Arthritis - Pipeline by KPI Therapeutics Inc, H2 2017
Psoriatic Arthritis - Pipeline by Morphotek Inc, H2 2017
Psoriatic Arthritis - Pipeline by Mycenax Biotech Inc, H2 2017
Psoriatic Arthritis - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2017
Psoriatic Arthritis - Pipeline by Novo Nordisk AS, H2 2017
Psoriatic Arthritis - Pipeline by Nuevolution AB, H2 2017
Psoriatic Arthritis - Pipeline by Oncobiologics Inc, H2 2017
Psoriatic Arthritis - Pipeline by Pfizer Inc, H2 2017
Psoriatic Arthritis - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017
Psoriatic Arthritis - Pipeline by Rigel Pharmaceuticals Inc, H2 2017
Psoriatic Arthritis - Pipeline by Sandoz International GmbH, H2 2017
Psoriatic Arthritis - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Psoriatic Arthritis - Pipeline by SynAct Pharma AB, H2 2017
Psoriatic Arthritis - Pipeline by UCB SA, H2 2017
Psoriatic Arthritis - Pipeline by Xbrane Biopharma AB, H2 2017
Psoriatic Arthritis - Dormant Projects, H2 2017
Psoriatic Arthritis - Dormant Projects, H2 2017 (Contd..1), H2 2017
Psoriatic Arthritis - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Psoriatic Arthritis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

3SBio Inc
AbbVie Inc
AbGenomics International Inc
Aclaris Therapeutics Inc
Adello Biologics LLC
Allergan Plc
Alteogen Inc
Amgen Inc
Biocon Ltd
Bionovis SA
Coherus BioSciences Inc
Eli Lilly and Co
Formycon AG
Forward Pharma AS
Fresenius SE & Co KGaA
Galapagos NV
Genor BioPharma Co Ltd
Immunwork Inc
Innovent Biologics Inc
Johnson & Johnson
KPI Therapeutics Inc
Morphotek Inc
Mycenax Biotech Inc
Nichi-Iko Pharmaceutical Co Ltd
Novo Nordisk AS
Nuevolution AB
Oncobiologics Inc
Pfizer Inc
Reliance Life Sciences Pvt Ltd
Rigel Pharmaceuticals Inc
Sandoz International GmbH
Sun Pharma Advanced Research Company Ltd
SynAct Pharma AB
UCB SA
Xbrane Biopharma AB
Skip to top


Rheumatoid Arthritis - Pipeline Review, H2 2016 US$ 2,500.00 Dec, 2016 · 1186 pages

Ask Your Question

Psoriatic Arthritis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: